CertaPath offers a Drug Sensitivity Testing (DST) platform that screens a patient’s own tumor tissue ex vivo to identify which FDA‑approved cancer therapies are most effective for that individual. By providing oncologists with concrete response data, the service enables personalized treatment selection, aiming to improve response rates and reduce exposure to ineffective drugs. The test is integrated into clinical workflows to support data‑driven oncology decisions.
Funding
Funding not disclosed
Founders
Product
Problem
Oncologists often rely on standard treatment protocols or genomic data that do not capture the functional response of an individual’s tumor, leading to low response rates and unnecessary toxicity for many cancer patients.
Solution
CertaPath offers an ex vivo drug sensitivity testing (DST) platform that screens a patient’s fresh tumor tissue against a library of over 200 FDA‑approved compounds. Within 14 days the service measures cancer cell death and compares it to normal tissue response, providing a dual assessment of efficacy and toxicity. A proprietary scoring algorithm translates these results into a ranked list of personalized treatment recommendations, highlighting drugs most likely to be effective while sparing healthy cells. The rapid turnaround and extensive drug panel enable clinicians to make data‑driven therapy choices for patients who have exhausted standard options, improving the likelihood of clinical response.
Target Audience
Primary customers are oncologists and cancer treatment centers seeking functional precision‑medicine data to guide therapy selection, particularly for patients with relapsed, refractory, or rare cancers.
Features
- Screening of fresh tumor specimens against 200+ FDA‑approved oncology drugs
- Simultaneous evaluation of tumor cell kill and normal tissue toxicity
- 14‑day result turnaround, significantly faster than alternative platforms
- Proprietary scoring algorithm that generates actionable, ranked treatment recommendations
- Cost‑effective per‑compound pricing at $28, offering an 87 % cost advantage over competitors
- Demonstrated clinical impact with a 60 % response rate in challenging cases